Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

Authors

Joel Picus, Washington University School of Medicine in St. Louis
et al

Journal

European Journal of Cancer

Publication Date

2018

Volume

94

Inclusive Pages

115-125

Document Type

Open Access Publication

DOI

10.1016/j.ejca.2018.02.012

Rights and Permissions

Choueiri TK, Hessel C, Halabi S, et al (2018) Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. European Journal of Cancer, 94:115-125. https://doi.org/10.1016/j.ejca.2018.02.012 https://doi.org/10.1016/j.ejca.2018.02.012 Copyright 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Picus, Joel and et al, "Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update." European Journal of Cancer. 94, 115-125. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/7202